http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1827470-A2
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43c45f12914ea665b21fb3b9713d8b9b |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2506-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2502-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2835 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0619 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0622 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5058 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5073 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0793 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-079 |
filingDate | 2005-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da94c184ec7426ff3a5e02e9efa07afc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c60ccf3656089fb78348266f10ec6f36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0939d2b2c0eb8220fdbe77f48c11274d |
publicationDate | 2007-09-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | EP-1827470-A2 |
titleOfInvention | Materials and methods related to dickkopfs (dkk) and neurogenesis |
abstract | Materials and Methods related to Dickkopfs and Neurogenesis Abstract Methods for promoting dopaminergic neuronal development and producing neural cells having a dopaminergic phenotype. Dopaminergic neural cells may be used for treating individuals having a neurodegenerative disease such as Parkinson's disease. Dopaminergic cells may be implanted into the brain of the individual, and/or dopaminergic neural development may be induced or enhanced in the brain of the individual. Methods comprise treating the cell with a Dkk ligand, such as any one of Dkk1 to Dkk4 or a fragment thereof comprising a cysteine rich domain, or a Dkk receptor such as LRP5 or LRP6, thereby producing or enhancing proliferation, self-renewal, survival and/or dopaminergic induction, differentiation, survival or acquisition of a neuronal dopaminergic phenotype. The cell may be co-cultured with astrocytes or glial cells and may be contacted with an FGF growth factor. Dopaminergic neurons may also be useful in drug/toxicology testing and for target development or drug discovery. |
priorityDate | 2004-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 616.